On Wednesday, Smith & Wesson Holding Corporation (NASDAQ:SWHC)’s shares surged 15.15% to $14.97.
Smith & Wesson Holding Corporation, declared that it is updating expectations for its fourth quarter and full 2015 fiscal year, which will end April 30, 2015. The company indicated that orders throughout its fiscal fourth quarter have been stronger than originally anticipated and it is therefore increasing its guidance.
Financial Outlook:
For the fourth quarter of fiscal 2015, the company anticipates net sales of between $175.0 million and $179.0 million and GAAP earnings per diluted share from ongoing operations of between $0.34 and $0.36. On a non-GAAP basis, the company anticipates earnings per diluted share to be between $0.39 and $0.41.
For full 2015 fiscal year, the company anticipates net sales of between $546.0 million and $550.0 million and GAAP earnings per diluted share from ongoing operations of between $0.84 and $0.86. On a non-GAAP basis, the company anticipates earnings per diluted share to be between $0.96 and $0.98.
Smith & Wesson Holding Corporation manufactures and sells firearm products in the United States and internationally. It offers firearms; handguns, counting revolvers and pistols; long guns, such as sporting, bolt action, and single shot rifles; hunting rifles; black powder firearms; handcuffs and restraints; and firearm-related products and accessories. The company sells its products under the Smith & Wesson, M&P, Thompson/Center Arms, and Performance Center brand names.
Key Energy Services Inc. (NYSE:KEG)’s shares gained 15% to $2.30, during the last trading session on Wednesday, as oil prices continued to climb for a second day.
WTI crude oil for May delivery was up 3.6% to $55.20 a barrel early Wednesday afternoon, and Brent crude oil for May delivery was up 2.1% to $59.63 a barrel.
The lower-than-predictable raise comes a day after the International Energy Agency declared that it anticipates global oil demand to raise by 1.1 million barrels a day in 2015, according to the Journal. The raise would be a “notable acceleration” from the 700,000 barrels a day growth seen in 2014, the agency said.
Key Energy Services, Inc. operates as an onshore rig-based well servicing contractor in the United States and internationally. It offers rig-based services, counting the maintenance, workover, and recompletion of existing oil wells; completion of newly-drilled wells; and plugging and abandonment of wells at the end of their lives, in addition to specialty drilling services to oil and natural gas producers.
At the end of Wednesday’s trade, Rosetta Genomics, Ltd. (NASDAQ:ROSG)’s shares gained 14.20% to $3.70.
Rosetta Genomics, declared the closing of its acquisition of CynoGen, Inc. (d/b/a PersonalizeDx) from Prelude Corporation.
PersonalizeDx is a rapidly growing molecular diagnostics and services company serving community-based pathologists, urologists, oncologists and other reference laboratories across the U.S. PersonalizeDx recorded revenues for 2014 of $6.9 million (unaudited), a nearly three-fold raise contrast with 2013 (unaudited). Through this transaction Rosetta Genomics gains proprietary tests in prostate, bladder and lung cancer, strong commercial and laboratory operations capabilities and a state-of-the-art, high-complexity CLIA laboratory in Lake Forest, California.
PersonalizeDx is focused on the detection of genomic changes through FISH technology, which assists to detect cancer, measure the potential aggressiveness of the disease and identify patients most likely to respond to targeted therapies. The company offers a “FISH Local” technical-only service option for all of its FISH-based tests, which allows pathologists to deliver expert case results to oncologists and urologists through reports that are customizable to the local pathology brand. The FISH service offered by PersonalizeDx is best-in-class with a highly competitive success rate in obtaining informative FISH results of 98% and excellent turnaround time of three to four days.
PersonalizeDx has the following additional novel content, which enables clinicians to practice personalized medicine:
- ERG is a proprietary prognostic test for patients with prostate cancer that provides urologists with results of favorable as compared to poor prognosis to assist inform the decision to proceed with surgery or active surveillance. This product is accessible as a global or technical-only FISH service and is offered in combination with PTEN for a comprehensive overall prognostic assessment. ERG was launched in 2014 and the annual U.S. market for ERG/PTEN testing is about $100 million.
- FGFR3 mutation analysis identifies low-grade bladder cancer from urine and tissue-based specimens. Test results assist urologists to monitor patients, and also assist with prognosis and tumor grading. When used in conjunction with the company’s leading FISH testing, the combined offering will provide a highly sensitive and specific diagnostic test for all stages of bladder cancer. FGFR3 addresses an annual U.S. market opportunity of about $250 million and is predictable to launch preceding to the end of 2015.
Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, counting Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that comprise carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples.
Finally, Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ended its Wednesday’s trading session with 13.83% gain, and closed at $10.70.
Foamix Pharmaceuticals, declared the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. All of the shares are being offered by the company. In addition, Foamix has granted the underwriters a 30-day option to purchase up to 967,741 additional ordinary shares. The offering is predictable to close on Monday, April 20, 2015, subject to customary closing conditions.
Barclays Capital Inc., Cowen and Company, LLC and Guggenheim Securities, LLC are acting as book-running managers for the offering. Oppenheimer & Co. Inc. is acting as co-manager.
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for the treatment of acne, impetigo, and other skin conditions in the United States, Germany, and Israel. Its lead product candidates comprise FMX101, a novel topical foam formulation which has accomplished a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has accomplished a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
